scholarly journals Radiotherapy for a rare phosphaturic mesenchymal tumor in the middle ear presenting with oncogenic osteomalacia

Medicine ◽  
2021 ◽  
Vol 100 (38) ◽  
pp. e27284
Author(s):  
Taiki Takaoka ◽  
Natsuo Tomita ◽  
Yoji Shido ◽  
Satoshi Baba ◽  
Mayu Fukushima ◽  
...  
2013 ◽  
Vol 04 (07) ◽  
pp. 24-27
Author(s):  
Eugenio Vecchini ◽  
Tommaso Maluta ◽  
Manuel Bondi ◽  
Francesco Perusi ◽  
Stefano Dall’Oglio ◽  
...  

2019 ◽  
Vol 7 (15) ◽  
pp. 2081-2086
Author(s):  
Dong Tang ◽  
Xiao-Man Wang ◽  
Yong-Sheng Zhang ◽  
Xiao-Xiao Mi

Medicina ◽  
2020 ◽  
Vol 56 (1) ◽  
pp. 34
Author(s):  
Cornelia Then ◽  
Evelyn Asbach ◽  
Harald Bartsch ◽  
Niklas Thon ◽  
Christian Betz ◽  
...  

A possible cause of hypophosphatemia is paraneoplastic secretion of fibroblast growth factor 23 (FGF-23). Tumors secreting FGF-23 are rare, mostly of mesenchymal origin, usually benign, and may be located anywhere in the body, including hands and feet, which are often not represented in conventional imaging. A 50-year-old woman presented with diffuse musculoskeletal pain and several fractures. Secondary causes of osteoporosis were excluded. Laboratory analysis revealed hypophosphatemia and elevated alkaline phosphatase, parathyroid hormone, and FGF-23. Thus, oncogenic osteomalacia due to neoplastic FGF-23 secretion was suspected. FDG-PET-CT and DOTATATE-PET-CT imaging demonstrated no tumor. Cranial MRI revealed a tumorous mass in the left cellulae ethmoidales. The tumor was resected and histopathological examination showed a cell-rich tumor with round to ovoid nuclei, sparse cytoplasm, and sparse matrix, resembling an olfactory neuroblastoma. Immunohistochemical analysis first led to diagnosis of olfactory neuroblastoma, which was later revised to phosphaturic mesenchymal tumor. Following the resection, FGF-23 and phosphate levels normalized. In conclusion, we here describe a patient with an FGF-23-secreting phosphaturic mesenchymal tumor with an unusual morphology. Furthermore, we emphasize diagnostic pitfalls when dealing with FGF-23-induced hypophosphatemia.


2020 ◽  
Vol 27 (3) ◽  
pp. 210-214
Author(s):  
Sandra Garrote-Corral ◽  
Walter Alberto Sifuentes-Giraldo ◽  
María Eugenia Reguero-Callejas ◽  
Mónica Vázquez-Díaz

2001 ◽  
Vol 30 (2) ◽  
pp. 99-103 ◽  
Author(s):  
A. Ogose ◽  
Tetsuo Hotta ◽  
Iwao Emura ◽  
Hiroshi Hatano ◽  
Yoshiya Inoue ◽  
...  

Author(s):  
Rishabh P. Acharya ◽  
Alexander M. Won ◽  
Amy C. Hessel ◽  
Mark S. Chambers ◽  
Robert F. Gagel

2006 ◽  
Vol 135 (4) ◽  
pp. 653-654 ◽  
Author(s):  
David M. Kaylie ◽  
C. Gary Jackson ◽  
Edward K. Gardner

2009 ◽  
Vol 10 (4) ◽  
pp. 329-333 ◽  
Author(s):  
Elena Pirola ◽  
Francesco Vergani ◽  
Paolo Casiraghi ◽  
Eugenio Biagio Leone ◽  
Paolo Guerra ◽  
...  

Phosphaturic mesenchymal tumors that cause the paraneoplastic syndrome known as oncogenic osteomalacia are rare. The authors report on the case of a 57-year-old man with a history of osteomalacia and in whom was diagnosed a thoracic spine tumor at the T-4 level. Complete tumor resection was accomplished. The histological diagnosis was phosphaturic mesenchymal tumor (mixed connective tissue variant). After lesion removal, the paraneoplastic syndrome resolved. At the 24-month follow-up, no recurrence of the disease was observed. The clinical presentation, surgical technique, and follow-up in this case were reviewed in detail.


Sign in / Sign up

Export Citation Format

Share Document